Hwasun Chonnam National University Hospital and NPK Join Forces for Microbiome-Based New Drug Development

Cooperation on Translational Research and Global New Drug Development

Presenting New Possibilities for Disease Treatment and Patient Care, Including Cancer Therapy

Hwasun Chonnam National University Hospital and NPK Co., Ltd. announced on August 10 that they have established a cooperative framework for new drug development and clinical research based on the microbiome.

Recently, Hwasun Chonnam National University Hospital signed a business agreement with NPK on the first floor of the Future Medical Innovation Center’s Kim Jaebong Hall to cooperate on non-clinical and clinical translational research utilizing microorganisms and microbial metabolites, as well as on global new drug development.

Officials including Injae Oh, Director of the Institute of Biomedical Science and Technology at Hwasun Chonnam National University Hospital, and Sangjun Kim, CEO of NPK, are posing for a commemorative photo after signing a business agreement on the 7th at the Kim Jaebong Hall in the Center for Future Medical Innovation. Provided by Hwasun Chonnam National University Hospital

At the signing ceremony, Oh Injae, Director of the Biomedical Research Institute at Hwasun Chonnam National University Hospital, Jo Sanghee, Director of the Clinical Trial Center, Sangjun Kim, CEO of NPK, and other related officials were in attendance. Choi Jooshik, CEO of Daewoodang Healthcare Co., Ltd., also participated.

Through this agreement, the two institutions will promote translational research and development focusing on microorganisms and microbial metabolites. In addition, they will collaborate on joint research for immune activity measurement and the design of clinical assessment indicators, as well as the utilization of research infrastructure.

In particular, they will work together to conduct clinical research on cancer supportive care (palliative therapy) and management of side effects of anticancer treatments based on microbial metabolites, aiming to bridge microbiology research results to actual patient care and clinical practice.

Furthermore, the two institutions plan to cooperate in building a microbiome platform and in regulatory affairs for global new drug development. Through these efforts, they intend to establish a research and development collaboration framework that connects basic and non-clinical research to clinical trials, new drug development, and commercialization.

Sangjun Kim, CEO of NPK, stated, "Through this agreement, we will pool the research capabilities of both institutions to create new research and development opportunities in the fields of microorganism and microbiome," adding, "We will strive to generate tangible cooperation outcomes that can lead to global new drug development."

Oh Injae, Director of the Biomedical Research Institute at Hwasun Chonnam National University Hospital, commented, "Research utilizing microorganisms and microbial metabolites is presenting new possibilities for the treatment and management of various diseases, including cancer therapy," and continued, "We will collaborate to connect the hospital’s clinical and research infrastructure with NPK’s technological expertise, ensuring that this leads to tangible achievements in clinical research and new drug development."

This content was produced with the assistance of AI translation services.